Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J STD AIDS ; 32(5): 444-448, 2021 04.
Article in English | MEDLINE | ID: mdl-33427080

ABSTRACT

Measurement of HIV viral load (VL) is the best indicator of success of antiretroviral therapy. We investigated the correlation between results by the Cepheid GeneXpert and a standard of care VL assay (Abbott M2000). This was a prospective study of people living with HIV who attended the department for routine VL measurement with the Abbott M2000. Consenting patients agreed to provide one extra blood sample for VL measurement with the Cepheid GeneXpert assay. One hundred patients consented to participate in the study. There were 18 patients with VL ≥ 40 copies/mL and 75 patients with VL < 40 copies on both assays. The two assays had 93% agreement, with a kappa of 0.79 (p < 0.001). Treating VL as a continuous variable found measurements to be significantly higher on the Cepheid GeneXpert assay than the Abbott (p = 0.002). Analysis of samples with VL ≥ 40 copies/mL on either assay (n = 25) found the mean difference between the two assays to be 0.31 log10 copies/mL (95% limits of agreement: -0.63, 1.25). Whilst the measurements on the two assays are relatively highly correlated, there is a clear bias, with the Cepheid GeneXpert tending to give higher VL values.


Subject(s)
HIV Infections , HIV-1 , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV-1/genetics , Humans , Prospective Studies , RNA, Viral , Viral Load
2.
J Acquir Immune Defic Syndr ; 73(3): 287-293, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27163175

ABSTRACT

U.K. guidelines for vaccinating HIV-infected adults against bacteria are based on limited data. We compared antibody responses between 211 HIV-infected and 73 HIV-uninfected adults vaccinated with pneumococcal polysaccharide vaccine (PPV) and Haemophilus influenzae b/meningococcal C polysaccharide-tetanus toxoid glycoconjugate vaccine (Hib/MenC-TT). IgG responses to Hib/MenC-TT were not significantly different. PPV induced median IgGs >1.3 µg/mL for 10/12 serotypes among HIV-uninfected participants and 5/12 in HIV-infected participants. HIV-uninfected adults had higher post-vaccination IgGs than HIV-infected adults for 4/12 serotypes (P < 0.001). Responses did not associate with CD4 count or viral suppression. In a U.K. HIV-infected population, Hib/MenC-TT induced similar responses to HIV-uninfected adults, whereas PPV induced poor responses.


Subject(s)
Antibodies, Bacterial/immunology , Bacterial Capsules/immunology , HIV Infections/complications , Haemophilus Vaccines/immunology , Immunization , Meningococcal Vaccines/immunology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/immunology , AIDS-Related Opportunistic Infections/immunology , AIDS-Related Opportunistic Infections/prevention & control , Adult , Female , HIV Infections/immunology , Haemophilus Vaccines/administration & dosage , Humans , Immunization Schedule , Male , Meningococcal Vaccines/administration & dosage , Pneumococcal Infections/immunology , Pneumococcal Vaccines/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...